Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21877621 | 1.00 | JAK2 (0.33) | JAK2JAK1TYK2NOS3NOS1 | |
| SCHEMBL21877759 | 0.78 | PRKACA (0.38) | JAK2JAK1TYK2 | |
| SCHEMBL21877758 | 0.78 | PRKACA (0.38) | JAK2JAK1TYK2 | |
| SCHEMBL21877671 | 0.75 | FFAR2 (0.34) | JAK2JAK1TYK2 | |
| SCHEMBL21877695 | 0.67 | NOS3 (0.33) | JAK2JAK1TYK2NOS3NOS1 | |
| SCHEMBL21877693 | 0.67 | NOS3 (0.33) | JAK2JAK1TYK2NOS3NOS1 | |
| SCHEMBL22687259 | 0.65 | USP2 (0.31) | — | |
| SCHEMBL5184422 | 0.65 | BRD4 (0.34) | — | |
| SCHEMBL16963893 | 0.65 | HCAR2 (0.39) | JAK2JAK1TYK2 | |
| SCHEMBL20931266 | 0.61 | IDO1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192833-B1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2026-01-21 | — | — | EP | disclosed |
| US-12473293-B2 | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2025-11-18 | — | — | US | disclosed |
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2023-09-14 | — | — | US | disclosed |
| EP-4192833-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2023-06-14 | — | — | EP | disclosed |
| CN-116075514-A | Pharmacologically active heterocyclic substituted pyrazolo [1,5-a ] pyrimidine derivatives | 吉瑞工厂 | 2023-05-05 | — | — | CN | disclosed |
| US-11026946-B2 | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2021-06-08 | — | — | US | disclosed |
| US-20200129515-A1 | Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | RICHTER GEDEON NYRT. (HU) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129515-A1 | Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | GABRA5, GABRA1, P2RX5 | JAK2 1239/4885JAK1 1339/4885TYK2 3727/4885 |
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | GABRA5, GABRA1, P2RX5 | JAK2 1103/4885JAK1 1269/4885TYK2 3829/4885 |
| US-12473293-B2 | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, GABRA1, P2RX5 | JAK2 1103/4885JAK1 1269/4885TYK2 3829/4885 |
| US-11026946-B2 | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, GABRA1, P2RX5 | JAK2 1239/4885JAK1 1339/4885TYK2 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.